Payment overview · 2025
General Payments
$147.10
8 reported records · 6 companies
Healthcare provider profile · identity verified
Aj Nixon, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · OMAHA, NE · NPI 1740481670
Verified facts
What the public records show
CMS Open Payments records show Aj Nixon, M.D. received $147.10 in general payments during 2025 across 8 reported records.
Exact Sciences Corporation accounted for 23.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 9 associated products.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 50 claims for Trulicity by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 57 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $34.66 | 23.6% | 2 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $32.11 | 21.8% | 2 | 2025 |
| HEARTFLOW, INC. | Unresolved — no canonical attribution shown | $25.35 | 17.2% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $22.42 | 15.2% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $17.37 | 11.8% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $15.19 | 10.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $147.10 | 8 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $32.11 | 2 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $32.11 | 2 | 2025 |
Source payment records
|
|||||
| FFRct Normalized: ffrct |
Device | HEARTFLOW, INC. | $25.35 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $22.42 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $19.90 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $17.37 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $15.19 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $15.19 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $14.76 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
28 | 13 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
50 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
57 | 18 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 610 | 173 |
| Levothyroxine Sodium | Levothyroxine Sodium | 283 | 77 |
| Lisinopril | Lisinopril | 259 | 73 |
| Amlodipine Besylate | Amlodipine Besylate | 216 | 66 |
| Omeprazole | Omeprazole | 208 | 57 |
| Metoprolol Succinate | Metoprolol Succinate | 199 | 59 |
| Losartan Potassium | Losartan Potassium | 178 | 51 |
| Simvastatin | Simvastatin | 156 | 42 |
| Gabapentin | Gabapentin | 145 | 45 |
| Pantoprazole Sodium | Pantoprazole Sodium | 135 | 39 |
| Tamsulosin Hcl | Tamsulosin Hcl | 134 | 45 |
| Metformin Hcl | Metformin Hcl | 121 | 31 |
| Sertraline Hcl | Sertraline Hcl | 112 | 27 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 104 | 27 |
| Zolpidem Tartrate | Zolpidem Tartrate | 103 | 21 |
| Allopurinol | Allopurinol | 93 | 29 |
| Finasteride | Finasteride | 80 | 25 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 77 | 22 |
| Alprazolam | Alprazolam | 76 | 21 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 76 | 25 |
| Montelukast Sodium | Montelukast Sodium | 75 | 27 |
| Carvedilol | Carvedilol | 72 | 18 |
| Celecoxib | Celecoxib | 71 | 25 |
| Metoprolol Tartrate | Metoprolol Tartrate | 70 | 18 |
| Trazodone Hcl | Trazodone Hcl | 68 | 29 |
| Alendronate Sodium | Alendronate Sodium | 67 | 18 |
| Escitalopram Oxalate | Escitalopram Oxalate | 67 | 18 |
| Clopidogrel | Clopidogrel Bisulfate | 64 | 19 |
| Tramadol Hcl | Tramadol Hcl | 62 | 31 |
| Prednisone | Prednisone | 61 | 32 |
| Fluticasone Propionate | Fluticasone Propionate | 60 | 26 |
| Eliquis | Apixaban | 57 | 18 |
| Bupropion Xl | Bupropion Hcl | 55 | 19 |
| Spironolactone | Spironolactone | 54 | 14 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 51 | 20 |
| Metformin Hcl Er | Metformin Hcl | 51 | 13 |
| Trulicity | Dulaglutide | 50 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 48 | 18 |
| Furosemide | Furosemide | 46 | 24 |
| Meloxicam | Meloxicam | 46 | 19 |
| Methocarbamol | Methocarbamol | 46 | 24 |
| Citalopram Hbr | Citalopram Hydrobromide | 42 | 17 |
| Glipizide | Glipizide | 41 | 13 |
| Ropinirole Hcl | Ropinirole Hcl | 41 | 11 |
| Warfarin Sodium | Warfarin Sodium | 41 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 40 | 15 |
| Atenolol | Atenolol | 39 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 38 | 12 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 37 | 20 |
| Sumatriptan Succinate | Sumatriptan Succinate | 37 | suppressed |
| Naproxen | Naproxen | 36 | 14 |
| Testosterone Cypionate | Testosterone Cypionate | 35 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 34 | suppressed |
| Niacin Er | Niacin | 34 | suppressed |
| Pregabalin | Pregabalin | 33 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 32 | suppressed |
| Ezetimibe | Ezetimibe | 31 | 11 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 30 | 28 |
| Duloxetine Hcl | Duloxetine Hcl | 30 | suppressed |
| Glimepiride | Glimepiride | 30 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 30 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 30 | suppressed |
| Chlorthalidone | Chlorthalidone | 29 | 11 |
| Ibandronate Sodium | Ibandronate Sodium | 29 | suppressed |
| Aripiprazole | Aripiprazole | 28 | suppressed |
| Jardiance | Empagliflozin | 28 | 13 |
| Quetiapine Fumarate | Quetiapine Fumarate | 28 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 27 | suppressed |
| Cephalexin | Cephalexin | 26 | 20 |
| Clonazepam | Clonazepam | 25 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 25 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 24 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 24 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 23 | suppressed |
| Methylprednisolone | Methylprednisolone | 22 | 20 |
| Amitriptyline Hcl | Amitriptyline Hcl | 21 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 21 | suppressed |
| Ibuprofen | Ibuprofen | 21 | suppressed |
| Levofloxacin | Levofloxacin | 21 | 18 |
| Lorazepam | Lorazepam | 21 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 21 | 11 |
| Varenicline Tartrate | Varenicline Tartrate | 21 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 19 | suppressed |
| Fenofibrate | Fenofibrate | 19 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 19 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 19 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 19 | suppressed |
| Famotidine | Famotidine | 18 | suppressed |
| Memantine Hcl | Memantine Hcl | 18 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 18 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 17 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 17 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 17 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 17 | 15 |
| Doxazosin Mesylate | Doxazosin Mesylate | 17 | suppressed |
| Mirtazapine | Mirtazapine | 17 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 17 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 17 | suppressed |
| Amoxicillin | Amoxicillin | 16 | 14 |
| Clonidine Hcl | Clonidine Hcl | 16 | suppressed |
| Estradiol | Estradiol | 16 | suppressed |
| Levetiracetam | Levetiracetam | 16 | suppressed |
| Potassium Chloride | Potassium Chloride | 16 | suppressed |
| Xarelto | Rivaroxaban | 16 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 15 | 13 |
| Ketoconazole | Ketoconazole | 15 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 15 | 12 |
| Propranolol Hcl Er | Propranolol Hcl | 15 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 15 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 15 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 14 | suppressed |
| Fluconazole | Fluconazole | 14 | 11 |
| Klor-Con M20 | Potassium Chloride | 14 | suppressed |
| Nabumetone | Nabumetone | 14 | suppressed |
| Testosterone | Testosterone | 14 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 13 | suppressed |
| Lovastatin | Lovastatin | 13 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 13 | suppressed |
| Azithromycin | Azithromycin | 12 | 12 |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 12 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 12 | suppressed |
| Diazepam | Diazepam | 12 | suppressed |
| Nitroglycerin | Nitroglycerin | 12 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 12 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 12 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 11 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 11 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 11 | suppressed |
| Nifedipine Er | Nifedipine | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $147.10 · 8 records | Exact Sciences Corporation | Cologuard Collection Kit, FFRct, MOUNJARO, NURTEC ODT, QULIPTA, REXULTI, The Cologuard Plus Collection Kit, UBRELVY, ZAVZPRET | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with Lilly USA, LLC?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error